A lyophilized peptide is a shelf-stable solid; a reconstituted one is a degrading solution on a clock. Storage temperature is the main dial controlling how fast that clock runs — and the pharmaceutical stability literature is unusually clear about which settings matter.
Lyophilized peptides: freezer storage (−20 °C) for the long term, refrigeration acceptable for working timescales, always protected from light and moisture. Reconstituted peptides: refrigerated at 2–8 °C, used within the in-use window, never repeatedly frozen and thawed.
Why temperature is the master variable
Peptide degradation is chemistry — hydrolysis, deamidation, oxidation, aggregation — and chemistry runs on temperature. The protein-pharmaceutical stability literature treats temperature as the dominant, always-present stress: reactions that take months at freezer temperature take weeks refrigerated and days on a desk. That relationship is why every storage recommendation is really a temperature recommendation with accessories.
The accessories matter too: light drives photo-oxidation, and moisture uptake turns a stable solid into a slowly reacting one. Dark and dry are not superstition; they remove two of the documented degradation routes.
Lyophilized powder: the stable state
Freeze-drying exists precisely because removing water suspends most degradation chemistry. In the lyophilized state, formulation work shows peptides tolerate storage far better than in solution — which is why research peptides ship as powder, and why the powder state is the one to preserve as long as possible.
Practice that follows from the data: store sealed vials at −20 °C for long holds, or refrigerated for material in active use; keep vials sealed against ambient humidity; let a cold vial reach room temperature before opening so condensation forms on the glass, not the cake.
After reconstitution: the clock starts
Water restores every solution-phase degradation pathway at once — hydrolysis, deamidation, aggregation at interfaces. The stability literature's consistent finding is that liquid formulations are the vulnerable state, and temperature control matters most exactly here: refrigerate reconstituted material at 2–8 °C and treat it as a dated solution, not a stored one.
Bacteriostatic water extends the microbiological in-use window — pharmacopeial guidance treats benzyl-alcohol-preserved diluent as a multi-dose tool measured in weeks — but preservation does not pause chemical degradation. The peptide is degrading on its own schedule regardless of how clean the solution stays.
Research peptides
Lyophilized research-use-only peptides with batch documentation — shipped as the stable solid the storage data favors.
Freeze–thaw: the underrated destroyer
Freezing a reconstituted peptide once for a long hold can be defensible; cycling it is not. Freeze–thaw stress concentrates solutes at the ice interface and drives aggregation — the stability literature treats repeated cycles as a standard damage model, not an edge case. If a solution must be frozen, single-use aliquots frozen once each are the pattern the data supports.
The temperature table
| State | Temperature | Horizon | Notes |
|---|---|---|---|
| Lyophilized, long-term | −20 °C | Months to years | Sealed, dark, dry; warm before opening |
| Lyophilized, in use | 2–8 °C | Weeks to months | Working stock; keep sealed between uses |
| Reconstituted | 2–8 °C | The in-use window | Dated, refrigerated, never room-temperature storage |
| Reconstituted, frozen | −20 °C | Single freeze only | Aliquot first; never refreeze a thawed aliquot |
Compound-specific stability varies — sequence, formulation and diluent all move the numbers — so the table is the conservative frame, not a per-compound guarantee. Where a supplier or monograph states a tighter window, the tighter window wins.
Research peptides
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
What to know now
- Temperature is the master variable — every documented degradation route runs faster warm.
- Lyophilized: −20 °C long-term, refrigerated in use, sealed against light and moisture.
- Reconstituted: 2–8 °C, treated as a dated solution — preservation extends the microbial window, not the chemical one.
- Freeze–thaw cycling is a standard damage model in the stability literature. Aliquot once; never refreeze.
- Warm cold vials before opening — condensation belongs on the glass, not in the cake.
What we're watching
Formulation work on room-temperature-stable peptide solids keeps advancing in pharma; if any of it reaches the research-supply market, the cold-chain conversation changes shape.
Frequently asked questions
What temperature should peptides be stored at?
Lyophilized (powder) peptides: −20 °C for long-term storage, or refrigerated at 2–8 °C while in active use, sealed and dark. Once reconstituted, refrigerate at 2–8 °C and use within the in-use window.
How long do peptides last in the fridge after reconstitution?
It depends on the compound and diluent, so treat published in-use windows as the ceiling. Bacteriostatic water controls microbial growth for a multi-week window under pharmacopeial multi-dose practice, but chemical degradation continues throughout — refrigeration slows it, nothing stops it.
Can you freeze reconstituted peptides?
Once, in single-use aliquots, if a long hold is unavoidable. Repeated freeze–thaw cycles drive aggregation and are treated as a standard damage model in the protein-stability literature — never refreeze a thawed aliquot.
Do peptides need to be shipped cold?
Lyophilized peptides tolerate ambient shipping windows — the solid state is the stable state, and days in transit at ambient temperature are a different exposure class from months of warm storage. Cold matters most after reconstitution.
References
- Wang, W. (1999). Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 185(2), 129–188. https://doi.org/10.1016/s0378-5173(99)00152-0
- Manning, M. C., Chou, D. K., Murphy, B. M., et al. (2010). Stability of protein pharmaceuticals: An update. Pharmaceutical Research, 27(4), 544–575. https://doi.org/10.1007/s11095-009-0045-6
- American Society of Health-System Pharmacists (ASHP). Handbook on Injectable Drugs: Benzyl alcohol preservative compatibility and stability data. https://www.ashp.org/products-and-services/database-tools/handbook-on-injectable-drugs
- United States Pharmacopeia. (2024). Bacteriostatic Water for Injection — monograph and in-use stability guidance. USP-NF. (See institutional access.) https://doi.org/10.4135/9781412963855.n1200
- Choi, Y. L., Park, E. J., Kim, E., Na, D. H., & Shin, Y.-H. (2014). Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS). Biomolecules & Therapeutics, 22(4), 321–327. https://doi.org/10.4062/biomolther.2014.053